Reported results
- As of September 30, 2026, Neumora had cash and cash equivalents of $85.7 million.
- Research and development expenses for the third quarter of 2026 were $22.6 million, compared to $40.5 million for the third quarter of 2025.
- General and administrative expenses for the third quarter of 2026 were $10.8 million, compared to $12.2 million for the third quarter of 2025.
- Net loss for the third quarter of 2026 was $34.4 million, compared to $56.8 million for the third quarter of 2025.
- Net loss per share, basic and diluted, was $0.18 for the third quarter of 2026, compared to $0.35 for the third quarter of 2025.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
